Implementing Pre-Therapeutic
UGT1A1
irinotecan
metastatic cancer
pharmacogenomics
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
02 Feb 2022
02 Feb 2022
Historique:
received:
28
12
2021
revised:
25
01
2022
accepted:
27
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Current guidelines recommend pre-therapeutic
Identifiants
pubmed: 35207692
pii: jpm12020204
doi: 10.3390/jpm12020204
pmc: PMC8875990
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Treat Rev. 2008 Nov;34(7):656-69
pubmed: 18558463
Eur J Cancer. 2020 Dec;141:9-20
pubmed: 33125947
Genet Med. 2009 Jan;11(1):21-34
pubmed: 19125129
Pharmacogenomics J. 2015 Dec;15(6):513-20
pubmed: 25778466
J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5
pubmed: 17728214
Cancer Sci. 2011 Oct;102(10):1868-73
pubmed: 21740478
Eur J Cancer. 2018 Aug;99:66-77
pubmed: 29909091
J Clin Oncol. 2009 May 20;27(15):2457-65
pubmed: 19364970
Eur J Cancer. 2022 Feb;162:148-157
pubmed: 34998046
Pharmacol Ther. 2014 Jan;141(1):92-116
pubmed: 24076267
Cancer. 1995 Jan 1;75(1):11-7
pubmed: 7804963
J Clin Oncol. 2007 May 1;25(13):1670-6
pubmed: 17470860
Fundam Clin Pharmacol. 2015 Jun;29(3):219-37
pubmed: 25817555
Nat Rev Clin Oncol. 2015 Oct;12(10):607-19
pubmed: 26215044
J Clin Oncol. 2006 Oct 1;24(28):4534-8
pubmed: 17008691
Semin Oncol. 2017 Feb;44(1):24-33
pubmed: 28395759
Hum Genomics. 2010 Apr;4(4):238-49
pubmed: 20511137
Cancer Sci. 2021 Nov;112(11):4669-4678
pubmed: 34327766
J Clin Oncol. 2009 Jun 1;27(16):2604-14
pubmed: 19349540
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):695-701
pubmed: 18349289
Br J Cancer. 2004 Aug 16;91(4):678-82
pubmed: 15280927
Br J Clin Pharmacol. 2006 Jul;62(1):35-46
pubmed: 16842377
Cancer Chemother Pharmacol. 2019 Jan;83(1):123-129
pubmed: 30377777
Clin Cancer Res. 2010 Aug 1;16(15):3832-42
pubmed: 20562211